Revisit the Top 5 OncLive On Air Episodes of 2023
In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.
Source: onclive.com
Terence Friedlander News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Terence Friedlander. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Terence Friedlander Today - Breaking & Trending Today
First-line Enfortumab Vedotin Plus Pembrolizumab Has Durable Activity in Urothelial Carcinoma
Responses achieved with enfortumab vedotin plus pembrolizumab were found to be rapid and durable in patients with previously untreated locally advanced or metastatic urothelial carcinoma who were cisplatin ineligible.
Source: onclive.com
FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
Dr Friedlander discusses the FDA approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma, key efficacy and safety data from the EV-103 trial, and the importance of incorporating this regimen into the frontline setting for this population.
Source: onclive.com
Enfortumab Vedotin With Pembrolizumab May Usher in New Standard for Treatment of Urothelial Carcinoma
Terence Friedlander, MD, discusses the significance of the FDA approval of enfortumab vedotin combined with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma, and expands on the data from the EV-103/KEYNOTE-869 trial that supported the approval.
Source: onclive.com
Dr. Friedlander on the FDA Approval of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer
Terence Friedlander, MD, discusses the significance of the FDA approval of frontline enfortumab vedotin combined with pembrolizumab in patients with urothelial carcinoma.
Source: onclive.com